Researchers at UCLA have shown that divergent neuronal signaling in fragile X mice converges on EPAC2, a druggable target whose inhibition restores circuit activity and alleviates core behavioral impairments. Read More
It is not surprising that a large Ebola outbreak would be considered a public health emergency of international concern. But the current PHEIC is notable for the speed with which it was declared, speaking to the urgency of the situation. World Health Organization Director-General Tedros Adhanom Ghebreyesus declared the outbreak a PHEIC on Sunday, May 17, without first convening an emergency committee. That step is unprecedented. Read More
Ichnos Glenmark Innovation Inc. has announced a new development candidate, ISB-2301, a potentially first-in-class, multispecific immune cell activator for the potential treatment of multiple solid tumor indications. ISB-2301 is a multispecific antibody that targets three tumor-associated antigens to trigger tumor cell death and engages both T and NK cells to activate the immune system. Leveraging the company’s BEAT technology, ISB-2301 is designed to induce potent antibody-dependent cellular cytotoxicity, checkpoint inhibition and a sustained type 1 immune response. Read More
Hangzhou Qihan Biotech Co. Ltd. has obtained IND clearance from the FDA for QT-019C, a universal allogeneic CAR T-cell therapy for autoimmune diseases. QT-019C cell injection is an off-the-shelf allogeneic CAR T-cell therapy engineered from healthy donor leukapheresis products to stably express two distinct CARs targeting CD19 and BCMA. Read More
Cereno Scientific AB plans to initiate preclinical disease model studies evaluating CS-585 in antiphospholipid syndrome, a rare autoimmune disease associated with recurrent blood clots and serious cardiovascular complications. The studies will be initiated this year under an ongoing research collaboration with the University of Michigan. Read More
Nextgen Bioscience Co. Ltd. has identified new sphingosine 1-phosphate S1P1 and S1P4 receptor antagonists potentially useful for the treatment of autoimmune diseases, ulcerative colitis and Crohn’s disease. Read More
Gertrude Biomedical Pty. Ltd. has patented new transcription factor SOX18 inhibitors potentially useful for the treatment of renal disorders, eye disorders and cancer. Read More
Recludix Pharma Inc. recently presented data on their new STAT1/3 inhibitors REX-6553 and REX-6547 for treating dermatological inflammatory skin diseases. Read More
Jiangsu Hansoh Pharmaceutical Group Co. Ltd. and Shanghai Hansoh Biomedical Co. Ltd. have discovered new phosphatidylinositol 3-kinase α (PI3Kα) H1047R mutant inhibitors potentially useful for the treatment of cancer, PIK3CA-related overgrowth spectrum (PROS), immune diseases and inflammatory diseases. Read More
Nanjing Reju Therapeutics Inc. has reported new nicotinamide phosphoribosyltransferase (NAmPRTase; Nampt) activators potentially useful for the treatment of atherosclerosis, Duchenne muscular dystrophy, heart failure, multiple sclerosis, obesity, cardiomyopathy, Alzheimer’s and Parkinson’s disease, among others. Read More
Pancreatic ductal adenocarcinoma (PDAC) is still a highly lethal cancer with limited therapeutic options. Its lethality mainly stems from activating KRAS mutations and a metabolic dependence on nicotinamide adenine dinucleotide (NAD). Researchers from Remedy Plan Inc. have presented data on RPT-E-037, which exerts dual targeting of NAD metabolism through Nampt inhibition and KRAS signaling inhibition using a pan-RAS inhibitor (RMC-6236). Read More
